Efekti subhroničnog unosa mineralne vode bogate magnezijum-karbonatom na kardiometaboličke markere i elektrolite u pacova sa dijabetesom izazvanim streptozotocinom
Sažetak
Background/Aim: Hypomagnesaemia is one of the most detected electrolyte abnormalities in diabetics. Modulation of numerous cardiovascular pathophysiological processes is a potential goal for anti-diabetic therapy. Magnesium supplementation prevents subclinical tissue magnesium deficiency, thus delaying the onset of metabolic imbalance in diabetes, but long-term effects of magnesium supplementation in chronic diabetes and numerous pathophysiological processes remain unknown. Aim of this study was to determine the effects of subchronic intake of magnesium hydrocarbonate-rich mineral water on cardiometabolic markers and electrolytes in rats with streptozotocin-induced diabetes.
Methods: A total of 28 Wistar, male rats, body weight 160 g at start, were divided into four groups of 7 each: two controls, group that drank tap water and received a single ip injection of saline (0.9 % NaCl) (TW-C), group that drank mineral water rich in magnesium hydrocarbonate and received a single ip injection of saline (0.9 % NaCl) (MW-C); and two experimental groups with streptozotocin-induced diabetes, group that drank tap water and received a single ip injection of streptozotocin (100 mg/kg) in saline (0.9 % NaCl, 1 mL) (TW-DM), group that drank mineral water rich in magnesium hydrocarbonate and received a single ip injection of streptozotocin (100 mg/kg) in saline (0.9 % NaCl, 1 mL) (MW-DM).
Results: Regarding the biochemical parameters, a decrease was observed in the MW-C group for vitamin B12 and proteins, while triglycerides were higher compared to the TW-C group. By comparing the haemostatic biomarkers between TW-C and MW-C groups, a statistically significant decrease was found for fibrinogen, while the electrolyte analysis showed an increase in phosphates for the MW-C group. Biochemical value comparison between TW-DM and MW-DM groups showed that magnesium hydrocarbonate usage in diabetic rats did not significantly reduce glycaemia although the average glycaemic values were lower in the group treated with magnesium hydrocarbonate. Regarding the electrolyte values, a statistically significant decrease was observed for sodium, potassium and phosphate in the MW-DM group. The MW-DM group also showed a significant increase in iron value compared to TW-DM group.
Conclusion: Subchronic intake of magnesium hydrocarbonate-rich mineral water, as a form of magnesium supplementation, did not cause a significant improvement in glycaemia or normalisation of diabetes-induced dyslipidaemia. This study showed the reduction of fibrinogen value, thus indicating the possibility of usage of this form of magnesium supplementation in different pro-thrombogenic conditions.
Reference
1. Mutavdzin S, Gopcevic K, Stankovic S, Jakovljevic Uzelac J, Labudovic Borovic M, Djuric D. The effects of folic acid administration on cardiac tissue matrix metalloproteinases activities and hepatorenal biomarkers in diabetic rats. Can J PhysiolPharmacol 2019;97(9):893-901.
Mutavdzin S, Gopcevic K, Stankovic S, Jakovljevic Uzelac J, Labudovic Borovic M, Djuric D. The effects of folic acid administration on cardiac oxidative stress and cardiovascular biomarkers in diabetic rats. Oxid Med Cell Longev 2019;2019:1-14.
Beckman J, Creager M. Vascular complications of diabetes. Circ Res 2016;118(11):1771-85.
Deluyker D, Evens L, Bito V. Advanced glycation end products (AGEs) and cardiovascular dysfunction: focus on high molecular weight AGEs. Amino Acids 2017;49(9):1535-41.
Hu X, Bai T, Xu Z, Liu Q, Zheng Y, Cai L. Pathophysiological fundamentals of diabetic cardiomyopathy. Compr Physiol 2017;7(2):693-711.
Peterson L, McKenzie C, Schaffer J. Diabetic cardiovascular disease: Getting to the heart of the matter. J Cardiovasc Transl Res 2012;5(4):436-45.
Forbes J, Cooper M. Mechanisms of diabetic complications. Physiol Rev 2013;93(1):137-88.
Grundy S, Benjamin I, Burke G, Chait A, Eckel R, Howard B, et al. Diabetes and cardiovascular disease. Circulation 1999;100(10):1134-46.
Liamis G, Liberopoulos E, Barkas F, Elisaf M. Diabetes mellitus and electrolyte disorders. World J Clin Cases 2014;2(10):488-96.
Sjogren A, Floren CH, Nilsson A. Magnesium deficiency in IDDM related to level of glycosylated hemoglobin. Diabetes 1986;35(4):459-63.
Atabek ME, Kurtoglu S, Pirgon O, Baykara M. Serum magnesium concentrations in type 1 diabetic patients: relation to early atherosclerosis. Diabetes Res Clin Pract 2006;72(1):42-7.
Nagase N. Hypertension and serum Mg in the patients with diabetes and coronary heart disease. Hypertens Res 1996;19(Suppl 1):S65-S68.
Del Gobbo LC, Song Y, Poirier P, Dewailly E, Elin RJ, Egeland GM. Low serum magnesium concentrations are associated with a high prevalence of premature ventricular complexes in obese adults with type 2 diabetes. Cardiovasc Diabetol 2012;11:23.doi: 10.1186/1475-2840-11-23.
Morakinyo AO, Samuel TA, Adekunbi DA. Magnesium upregulates insulin receptor and glucose transporter-4 in streptozotocin-nicotinamide-induced type-2 diabetic rats. Endocr Regul 2018;52(1):6-16.
Mubagwa K, Gwanyanya A, Zakharov S, Macianskiene R. Regulation of cation channels in cardiac and smooth muscle cells by intracellular magnesium. Arch Biochem Biophys 2007;458(1):73-89.
Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J 2012;5(Suppl 1):i3-i14.
Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev 2013;24(2):47-66.
de Rouffignac C, Quamme, G. Renal magnesium handling and its hormonal control. Physiol Rev 1994;74(2):305-22.
Quamme G, de Rouffignac C. Epithelial magnesium transport and regulation by the kidney. Front Biosci 2000;5:D694-D711.
Touyz R. Magnesium in clinical medicine. Front Biosci 2004;9:1278-93.
Seo J, Park T. Magnesium metabolism. Electrolyte & Blood Press 2008;6(2):86-95.
Amoni M, Kelly-Laubscher R, Blackhurst D, Gwanyanya A. Beneficial effects of magnesium treatment on heart rate variability and cardiac ventricular function in diabetic rats. J Cardiovasc Pharmacol Ther 2017;22(2):169-78.
Morakinyo A, Samuel T, Adekunbi D. Magnesium upregulates insulin receptor and glucose transporter-4 in streptozotocin-nicotinamide-induced type-2 diabetic rats. Endocr Regul 2018;52(1):6-16.
Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, et al. Experimental NIDDM: Development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 1998;47(2):224-9.
Masiello P. Animal models of type 2 diabetes with reduced pancreatic β-cell mass. Int J Biochem Cell Biol 2006;38(5-6):873-93.
Festa A, Williams K, D’Agostino R Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals: The insulin resistance atherosclerosis study. Diabetes 2006;55:1114-20.
Taheri Rouhi S, Sarker M, Rahmat A, Alkahtani S, Othman F. The effect of pomegranate fresh juice versus pomegranate seed powder on metabolic indices, lipid profile, inflammatory biomarkers and the histopathology of pancreatic islets of Langerhans in streptozotocin-nicotinamide induced type 2 diabetic Sprague–Dawley rats. BMC Complement Altern Med 2017;17(1):156. doi: 10.1186/s12906-017-1667-6.
Mooren FC, Kruger K, Volker K, Golf SW, Wadepuhl M, Kraus A. Oral magnesium supplementation reduces insulin resistance in non-diabetic supplementation reduces insulin resistance in non-diabetic subjects - a double-blind, placebo-controlled, randomized trial. Diabet Obes Metab 2011;13:281-4.
Song Y, He K, Levitan EB, Manson JE, Liu S. Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet Med 2006;23:1050-6.
Hruby A, Ngwa JS, Renstrom F, Wojczynski MK, Ganna A, Hallmans G. Higher magnesium intake is associated with lower fasting glucose and insulin, with no evidence of interaction with select genetic loci, in a meta-analysis of 15 CHARGE Consortium Studies. J Nutr 2013;143:345-53.
DiNicolantonio J, Liu J, O’Keefe J. Magnesium for the prevention and treatment of cardiovascular disease. Open Heart 2018;5(2):e000775. doi: 10.1136/openhrt-2018-000775.
Rayssiguier Y. Role of magnesium and potassium in the pathogenesis of arteriosclerosis. Magnesium 1984;3(4-6):226-38.
Shah NC, Liu JP, Iqbal J, Hussain M, Jiang XC, Li Z, et al. Mg deficiency results in modulation of serum lipids, glutathione and NO synthase isozyme activation in cardiovascular tissues: relevance to de novo synthesis of ceramide, serum Mg and atherogenesis. Int J Clin Exp Med 2011;4(2):103-18.
Parsons R, Butler T, Sellars E. The treatment of coronary artery disease with parenteral magnesium sulphate. Med Proc 1959;5:487-98.
Jeppesen B. Magnesium status in patients with acute myocardial infarction: a pilot study. Magnesium 1986;5(2):95-100.
Lox C, Dorsett M, Hampton R. Observations on clotting activity during pre-eclampsia. Clin Exp Hypertens B 1983;2(2):179-90.
Cantón R, Manzanares J, Alvarez E, Zaragozá F. In vitro and in vivo antiaggregant effects of magnesium halogenates. Thromb Haemost 1987;58(4):957-9.
Paolisso G, Tirelli A, Coppola L, Verrazzo G, Pizza G, Sgambato S. et al. Magnesium administration reduces platelet hyperaggregability in NIDDM. Diabetes Care 1989;12(2):167-8.
Boyd JC, Bruns DE, DiMarco JP, Sugg NK, Wills MR. Relationship of potassium and magnesium concentrations in serum to cardiac arrhythmias. Clin Chem 1984;30(5):754-7.
Dyckner T, Wester P. Potassium/magnesium depletion in patients with cardiovascular disease. Am J Med 1987;82(3):11-7.
Hollifield J. Potassium and magnesium abnormalities: Diuretics and arrhythmias in hypertension. Am J Med 1984;77(5):28-32.
Hollifield J. Thiazide treatment of hypertension: Effects of thiazide diuretics on serum potassium, magnesium and ventricular ectopy. Am J Med 1986;80(4):8-12.
Dyckner T, Wester P. Relation between potassium, magnesium and cardiac arrhythmias. Acta Med Scand Suppl 2009;209(S647):163-9.
Dyckner T, Wester P. Ventricular extrasystoles and intracellular electrolytes before and after potassium and magnesium infusions in patients on diuretic treatment. Am Heart J 1979;97(1):12-8.
Araújo Sampaio F, Monte Feitosa M, Hermes Sales C, Costa e Silva DM, Clímaco Cruz KJ, Oliveira FE, et al. Influence of magnesium on biochemical parameters of iron and oxidative stress in patients with type 2 diabetes. Nutr Hosp 2014;30(3):570-6.
Shi ZM, Hu XS, Yuan BJ, Gibson R, Dai Y, Garg M. Association between magnesium: iron intake ratio and diabetes in Chinese adults in Jiangsu Province. Diabet Med 2008;25(10):1164-70.
Sanchez-Morito N, Planells E, Aranda P, Llopis J. Influence of magnesium deficiency on the bioavailability and tissue distri¬ bution of iron in the rat. J Nutr Biochem 2000;11:103-8.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).